China Net Finance, February 26 (Reporter Xing Nan Ye Qian) On February 26, Borui Pharmaceutical (688166SH) released a performance express report showing that the company will achieve a total operating income of 120 billion yuan, a year-on-year increase of 1796%；Achieved net profit attributable to the parent company of 20.1 billion yuan, a year-on-year decrease of 1630%；Realized net profit attributable to the parent company after deducting non-profit 18.1 billion yuan, a year-on-year decrease of 1513%。
Regarding the decrease in net profit, Borui Pharmaceutical said: "It is mainly due to the increase in R&D expenses due to the increasing R&D investment in innovative drugs and inhalation preparations such as BGM0504 injection, and the increase in interest expenses due to the increase in interest expenses due to foreign currency interest rate hikes. ”
It is reported that BGM0504 injection is known as "** drug" by the market. According to the announcement of Borui Pharmaceutical, BGM0504 injection weight loss and type 2 diabetes** have both obtained the ethics approval for phase II clinical trials, of which the phase II clinical trial of type 2 diabetes** has begun to enroll. Peptide hypoglycemic drug BGM0504 injection is a dual agonist of GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide) receptors independently developed by the company, which can activate the downstream pathways of GIP and GLP-1, produce biological effects such as blood sugar control, weight loss and **nonalcoholic steatohepatitis (NASH), and show the potential of a variety of metabolic diseases.
Investors and investment institutions are very concerned about BGM0504 injection. In the institutional investigation on January 18, some institutions asked about the follow-up clinical rhythm of BGM0504, and Borui Pharmaceutical said: "After the completion of the phase II clinical trial, it is still necessary to confirm the confirmatory clinical trial plan by the State Food and Drug Administration, carry out and complete the phase III clinical study, and be reviewed and approved by the State Food and Drug Administration before it can be produced and marketed." ”
At the news level, the concept of ** medicine has been very hot recently, and a number of ** drug concept stocks once rose to the limit on February 20. According to the Times, under the influence of the movie "Hot and Hot", during the Spring Festival, the sales of drugs on platforms such as Jingdong and Douyin showed an upward trend.
*Although the concept of medicine has attracted much attention from the market, listed companies should also disclose information in accordance with laws and regulations. On October 18, 2023, China Net Finance issued the "Chairman of Borui Pharmaceutical Receives a Warning Letter for Misleading Remarks of "Testing Drugs by Himself" and is Accused of "Speculation"", pointing out that Yuan Jiandong, chairman of Borui Pharmaceutical, has raised the stock price by "testing the drug" remarks to boost the stock price, causing controversy, and the chairman was issued a warning letter because the relevant remarks are misleading.